Form 4: Neumora Therapeutics Director's Stock Options Repriced Following Shareholder Approval

Neumora Therapeutics, Inc. (NMRA) announced that its stockholders approved the repricing of stock options for Director Maykin Ho and other key personnel, significantly lowering the exercise price to $0.72 per share.

Summary

• On May 28, 2025, Neumora Therapeutics, Inc. (NMRA) stockholders approved the repricing of outstanding stock options held by members of the Board, certain employees, and other service providers.
• Director Maykin Ho's existing stock options, previously exercisable at $1.69 per share, were repriced to an exercise price of $0.72 per share.
• The repricing affects 95,586 options with an expiration date of April 23, 2031; 27,802 options expiring September 14, 2033; and 28,571 options expiring June 13, 2034.
• All other terms of these repriced options remain unchanged, and they are fully vested and exercisable.
• The repricing is contingent upon the Reporting Person (Maykin Ho) remaining in service to the Issuer through August 13, 2026.
• Additionally, Maykin Ho was granted 80,000 new stock options at an exercise price of $0.72 per share, which vest 100% on the earlier of the one-year anniversary of May 28, 2025, or immediately prior to the next Annual Meeting following May 28, 2025, and expire on May 27, 2035.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative to neutral. While the repricing aims to re-incentivize key personnel and retain talent, the necessity of such an action typically signals past stock underperformance. It's a positive for management retention but a potential negative signal regarding past shareholder value creation.

Positives

• The repricing of stock options at a lower exercise price of $0.72 per share re-incentivizes Director Maykin Ho and other key personnel, potentially aligning their interests more closely with future stock price appreciation.
• The new grant of 80,000 stock options further strengthens incentives for continued service and performance.
• Stockholder approval of the repricing indicates a collective decision to retain and motivate key talent, which is crucial for the company's long-term strategy.

Negatives

• The need for an option repricing from $1.69 to $0.72 per share typically suggests a significant decline in the company's stock price since the original grant, indicating past underperformance.
• Option repricing can be viewed negatively by some shareholders as it effectively transfers value from existing shareholders to option holders by lowering the hurdle for profitability.
• The new option grant and repricing could lead to increased potential dilution if a significant number of these options are exercised in the future.

Risks

• The repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026, posing a risk if the condition is not met.
• If the company's stock price continues to underperform, even the repriced options may not provide sufficient incentive, or further repricing could be sought, leading to additional shareholder value transfer.
• The market may interpret the repricing as a signal of past operational or financial challenges, potentially impacting investor confidence.

Future Outlook

The repricing and new grant of stock options are forward-looking actions designed to re-incentivize key personnel, including Director Maykin Ho, by aligning their compensation more closely with potential future stock price appreciation. This suggests management's belief in the company's ability to create future value and a strategic effort to retain talent through August 2026 and beyond.

Management Comments

• "On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."
• "On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the 'Repricing') of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."

Industry Context

Option repricing is a common practice in industries, particularly biotechnology and pharmaceuticals, where stock prices can be highly volatile and subject to significant declines due to clinical trial results, regulatory hurdles, or market sentiment. Companies often resort to repricing to re-motivate and retain key executives and directors when their original options are significantly 'underwater' (i.e., the exercise price is higher than the current market price), ensuring continued alignment of incentives despite past stock performance.

Comparison to Industry Standards

• Option repricing, while a tool for retention and re-incentivization, is generally viewed with caution by corporate governance advocates and institutional investors. It can be seen as a transfer of value from shareholders to management, especially if not accompanied by significant performance hurdles or if the original grants were not tied to rigorous performance metrics.
• Compared to companies like Biogen (BIIB) or Amgen (AMGN), which have more mature product portfolios and stable revenue streams, smaller biotech firms like Neumora Therapeutics (NMRA) often face higher volatility, making option repricing a more frequent consideration to maintain competitive compensation packages for talent.
• Best practices in executive compensation often suggest linking option grants to specific performance milestones (e.g., clinical trial success, regulatory approvals) rather than solely time-based vesting, which is not explicitly detailed for the repriced options beyond the service condition. The new grant, however, has a time-based vesting schedule.
• While specific comparable repricing events are not detailed in the document, the magnitude of the repricing (from $1.69 to $0.72) suggests a substantial drop in the company's stock price, which would typically trigger similar discussions in other biotech firms facing significant market value erosion.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased dilution from the lower exercise price and new option grants. The repricing may also signal past underperformance, potentially impacting investor confidence.
• Employees and Directors (including Maykin Ho): Re-incentivized by the lower exercise price, making their options more likely to be 'in the money' and providing stronger motivation for future performance and retention.

Next Steps

• Director Maykin Ho is expected to remain in service to Neumora Therapeutics through August 13, 2026, as a condition for the repricing.
• The 80,000 newly granted stock options will vest on the earlier of May 28, 2026 (one-year anniversary) or immediately prior to the next Annual Meeting following May 28, 2025.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, SEC Form 4, stock options, option repricing, executive compensation, director compensation, corporate governance, insider transaction, equity incentives